Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Zhang, Mei Fang ^a,b   Zhang, Zhi Yi ^a,b   Fu, Jia ^a,b   Yang, Yu Feng ^a,b   Yun, Jing Ping ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN MDM2; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MDM2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; TISSUE LEVEL; WESTERN BLOTTING; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74549178441     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-110     Document Type: Article

References (40)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543. 10.1016/S1470-2045(01)00486-7, 11905707.
2. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928. 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E, 2990661.
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331. 10.1016/S0092-8674(00)81871-1, 9039259.
4. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994, 54:3391-3395.
5. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825. 10.1016/0092-8674(93)90500-P, 8242752.
6. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993, 13:4107-4114. 359960, 7686617.
7. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 1998, 18:5690-5698. 109155, 9742086.
8. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003, 1:1001-1008.
9. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998, 18:555-564.
10. Qin LF, Ng IO. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol 2001, 32:778-784. 10.1053/hupa.2001.27105, 11521219.
11. Schoniger-Hekele M, Hanel S, Wrba F, Muller C. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 2005, 25:62-69. 10.1111/j.1478-3231.2004.0997.x, 15698400.
12. Sung CO, Yoo BC, Koh KC, Cho JW, Park CK. Prognostic significance of p53 overexpression after hepatic resection of hepatocellular carcinoma. Korean J Gastroenterol 2005, 45:425-430.
13. Terris B, Laurent-Puig P, Belghitti J, Degott C, Henin D, Flejou JF. Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. Int J Cancer 1997, 74:614-619. 10.1002/(SICI)1097-0215(19971219)74:6<614::AID-IJC10>3.0.CO;2-5, 9421358.
14. Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 2008, 98(5):349-57. 10.1002/jso.21109, 18646041.
15. Kao JT, Chuah SK, Huang CC, Chen CL, Wang CC, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, et al. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection. Liver Int 2007, 27:772-781. 10.1111/j.1478-3231.2007.01499.x, 17617120.
16. Bahnassi AA, Zekri AR, El-Houssini S, Mokhtar NM, Abdel-Aziz AO, Sherif GM, El-Mishad AM, Khaled HM. Hepatitis C virus-NS3P in relation to p53, p21waf, mdm2, p21-ras and c-erbB2 in hepatocarcinogenesis. J Gastroenterol Hepatol 2005, 20:1731-1740. 10.1111/j.1440-1746.2005.04002.x, 16246194.
17. Miao J, Chen GG, Chun SY, Lai PP. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett 2006, 236:115-124. 10.1016/j.canlet.2005.05.014, 15990224.
18. Yun JP, Chew EC, Liew CT, Chan JY, Jin ML, Ding MX, Fai YH, Li HK, Liang XM, Wu QL. Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J Cell Biochem 2003, 90:1140-1148. 10.1002/jcb.10706, 14635188.
19. Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, Wu QL, Rong TH. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases. BMC Cancer 2007, 7:38. 10.1186/1471-2407-7-38, 1829164, 17335582.
20. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007, 43:979-992. 10.1016/j.ejca.2007.01.004, 17291746.
21. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994, 54:1169-1174.
22. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704. 10.1038/366701a0, 8259214.
23. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76:1013-1023. 10.1016/0092-8674(94)90379-4, 8137420.
24. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Dalla Palma P, et al. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996, 12:1319-1324.
25. Tron VA, Tang L, Yong WP, Trotter MJ. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol 1996, 149:1139-1146. 1865206, 8863663.
26. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995, 55:2910-2919.
27. Lukas J, Groshen S, Saffari B, Niu N, Reles A, Wen WH, Felix J, Jones LA, Hall FL, Press MF. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 1997, 150:167-175. 1858522, 9006333.
28. Qin LF, Ng IO, Fan ST, Ng M. p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998, 79:424-428. 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4, 9699537.
29. Albrecht JH, Meyer AH, Hu MY. Regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1/Sdi1) gene expression in hepatic regeneration. Hepatology 1997, 25:557-563. 10.1002/hep.510250311, 9049198.
30. Wagayama H, Shiraki K, Yamanaka T, Sugimoto K, Ito T, Fujikawa K, Takase K, Nakano T. p21WAF1/CTP1 expression and hepatitis virus type. Dig Dis Sci 2001, 46:2074-2079. 10.1023/A:1011977923941, 11680578.
31. Wagayama H, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Yamanaka T, Takase K, Nakano T. High expression of p21WAF1/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol 2002, 33:429-434. 10.1053/hupa.2002.124724, 12055678.
32. Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, et al. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep 2007, 18:1417-1426.
33. Bandoh N, Hayashi T, Takahara M, Kishibe K, Ogino T, Katayama A, Imada M, Nonaka S, Harabuchi Y. Loss of p21 expression is associated with p53 mutations and increased cell proliferation and p27 expression is associated with apoptosis in maxillary sinus squamous cell carcinoma. Acta Otolaryngol 2005, 125:779-785. 10.1080/00016480410023056, 16012042.
34. Bahnassy AA, Zekri AR, Abdallah S, El-Shehaby AM, Sherif GM. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival. Pathol Int 2005, 55:53-62. 10.1111/j.1440-1827.2005.01804.x, 15693850.
35. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 2006, 19:69-74. 10.1038/modpathol.3800484, 16258514.
36. Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int 2006, 97:644-648. 10.1111/j.1464-410X.2006.06054.x, 16469041.
37. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Holscher AH, Monig SP. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 2008, 19:1477-1483.
38. Seo YH, Joo YE, Choi SK, Rew JS, Park CS, Kim SJ. Prognostic significance of p21 and p53 expression in gastric cancer. Korean J Intern Med 2003, 18:98-103.
39. Schmider A, Gee C, Friedmann W, Lukas JJ, Press MF, Lichtenegger W, Reles A. p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol 2000, 77:237-242. 10.1006/gyno.2000.5748, 10785471.
40. Dogan E, Saygili U, Tuna B, Gol M, Gurel D, Acar B, Koyuncuoglu M. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005, 97:46-52. 10.1016/j.ygyno.2004.12.053, 15790436.